Literature DB >> 11369836

Ambulatory blood pressure after renal transplantation.

F Fernández-Vega1, F Tejada, J Baltar, A Laures, E Gómez, J Alvarez.   

Abstract

Renal transplantation has been a usual medical practice in developed countries for several decades. A large number of studies report the excellent results obtained with such a practice. The survival of the graft, although able to be improved, is excellent and gives a great deal of hope to patients with renal insufficiency. The high level of investigation into immunosuppressor drugs offers, almost continuously, more efficient and better tolerated products. Paradoxically, the usual problems of patients with a renal transplant are not immunological but cardiovascular. Elevated serum cholesterol levels, obesity, diabetes and other cardiovascular risk factors (CVRFs) are usual in these patients, arterial hypertension (AHT) being the most frequent. Nephrologists are increasingly using ambulatory blood pressure monitoring (ABPM) on a daily basis. In the last 10 years, we have obtained highly valuable and interesting results with this technique which have allowed us to study and understand with greater precision the relationship of AHT to the kidney. Here we analyse and review the most relevant aspects of ABPM in the different stages of kidney disease, with special emphasis on renal transplantation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369836     DOI: 10.1093/ndt/16.suppl_1.110

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  2 in total

Review 1.  Ambulatory blood pressure and cardiovascular risk in chronic kidney disease.

Authors:  Paolo Palatini
Journal:  Curr Hypertens Rep       Date:  2008-04       Impact factor: 5.369

2.  Ambulatory Blood Pressure Monitoring and Echocardiographic Findings in Renal Transplant Recipients.

Authors:  Ozlem Kendirlinan Demirkol; Meric Oruc; Baris Ikitimur; Sevgi Ozcan; Sibel Gulcicek; Hikmet Soylu; Sinan Trabulus; Mehmet Riza Altiparmak; Nurhan Seyahi
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-12-22       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.